MA-VERACODE
Veracode, a leading global provider of application security solutions today announced that TA Associates (“TA”), a leading global growth private equity firm, has signed a definitive agreement to make a significant growth investment in the company. Veracode’s current majority investor, Thoma Bravo, a leading software investment firm, will retain a minority position in the business. The transaction, which values Veracode at $2.5B, is expected to be completed in Q2 2022, subject to customary closing conditions.
An eight-time leader in the Gartner Magic Quadrant for Application Security Testing, Veracode offers a comprehensive software security platform that empowers organizations to deliver secure software at scale and with unmatched speed.
"What we do has never been more crucial,” said Sam King, CEO of Veracode. “The confluence of digital transformation, software supply chain complexity, and the strengthening regulatory environment places software security firmly in the spotlight. We’re grateful for Thoma Bravo’s partnership over the last three years and look forward to our next chapter with TA. Together, we aim to accelerate our vision to deliver the most comprehensive software security platform that caters to the needs of both development teams and security teams by enabling them to build and deliver secure software at the speed that business demands.”
Under pressure by the ever-accelerating pace of digital transformation, software development teams are often forced to make tradeoffs between speed of delivery and the security of the software they deploy. Veracode’s platform balances the needs of both development and security teams by streamlining workflows to help customers ensure that software is coded securely without compromising speed while providing a comprehensive view of software security posture through powerful reporting and analytics. Collectively, Veracode customers have scanned over 53 trillion lines of code and fixed more than 71 million security flaws. With more than 2600 customers and nearly two-thirds of its revenue generated from large enterprise companies, the business has consistently outpaced growth forecasts for spending growth in application security.
“TA recognizes the strong market opportunity for Veracode, driven by the need to secure software and educate developers,” said Jason Werlin, a Managing Director at TA. "We believe Veracode's heritage and sustained leadership position, along with the breadth and depth of its portfolio, uniquely positions the company to drive the next wave of growth in the application security market. TA is excited to partner with the Veracode management team and Thoma Bravo on the next phase of the company’s journey.”
“Over the last three years, Veracode has expanded its platform, extended its market footprint, and established a clear track record of sustained innovation,” said Seth Boro, a Managing Partner at Thoma Bravo. “In today’s digital world, cybersecurity solutions are more critical than ever before, and Veracode continues to drive innovation while helping solve customers’ most complicated security needs. We are very proud of what Veracode has achieved under our majority ownership and look forward to continuing to support Veracode as it enters its next phase of growth in partnership with TA.”
“We are committed to our mission, strategy, and product vision,” continued King, “and we are excited to partner with TA, leveraging its significant experience investing in enterprise software companies and track record in scaling growth businesses, to realize that vision. We plan to invest in the expansion of our product portfolio through organic development and strategic M&A, as well as accelerate the expansion of our global footprint and growth, while maintaining the healthy business fundamentals we have achieved over the last few years.”
Continued expansion of Veracode’s talented team around the world is central to its growth objectives. The company is hiring talent in engineering, product management, marketing, sales, and customer success. Today, Veracode’s more than 725 team members around the world embrace remote and hybrid work models and are committed to the company’s mission to ensure that the software that powers our world is secure.
Deutsche Bank Securities Inc. is serving as exclusive financial advisor to Veracode and Thoma Bravo, and leading and providing committed debt financing to TA for the transaction. Barclays is serving as financial advisor to TA. Kirkland & Ellis is acting as legal counsel to Thoma Bravo and Goodwin Procter is serving as legal counsel to TA.
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities.
Learn more at www.veracode.com , on the Veracode blog and on Twitter.
Copyright © 2022 Veracode, Inc. All rights reserved. All other brand names, product names, or trademarks are the property of their respective holders.
About TA Associates
TA is a leading global growth private equity firm. Focused on targeted sectors within five industries – technology, healthcare, financial services, consumer and business services – the firm invests in profitable, growing companies with opportunities for sustained growth, and has invested in more than 550 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in high quality growth companies. TA has raised $47.5 billion in capital since its founding in 1968. The firm’s more than 100 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. More information about TA can be found at www.ta.com .
About Thoma Bravo
Thoma Bravo is one of the largest private equity firms in the world, with more than $91 billion in assets under management as of September 30, 2021. The firm invests in growth-oriented, innovative companies operating in the software and technology sectors. Leveraging the firm's deep sector expertise and proven strategic and operational capabilities, Thoma Bravo collaborates with its portfolio companies to implement operating best practices, drive growth initiatives and make accretive acquisitions intended to accelerate revenue and earnings. Over the past 20 years, the firm has acquired or invested in more than 350 companies representing over $155 billion in enterprise value. The firm has offices in Chicago, Miami and San Francisco. For more information, visit www.thomabravo.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005831/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
